Ind-Swift Laboratories Limited shareholders approved the issuance of up to 70,00,000 Fully Convertible Warrants (FCWs) to promoter group entities on August 5, 2026, with 99.99% support. The resolution passed during an Extraordinary General Meeting (EGM), clearing the path for a capital raise estimated at ₹137.20 crore assuming 100% conversion. This decisive backing validates the company’s strategy to fund expansion in its pharmaceutical formulations business through internal equity financing rather than debt, ensuring operational liquidity and manufacturing upgrades without diluting existing public shareholding significantly.

The EGM, chaired by Chairman Navrattan Munjal, saw robust participation from both promoter and public shareholders. A total of 53,86,48,49 votes were polled, representing 61.94% of outstanding shares held by the 40,239 shareholders on the record date of July 29, 2026. Voting was conducted exclusively via remote e-voting and electronic voting at the EGM venue, facilitated by Central Depository Services (India) Limited (CDSL). Vishal Arora, Company Secretary in practice, served as the scrutinizer, confirming the process complied with Section 108 of the Companies Act, 2013 and SEBI Listing Regulations.

Voting Results Breakdown

Shareholder support was nearly unanimous across all three special resolutions considered. For the warrant issuance, promoter entities voted 100% in favor, while public non-institutional investors approved the measure with 99.99% support. Only 596 votes were cast against the warrant resolution out of over 53 million polled. Similarly, the re-appointment of Rajinder Kumar Gupta as an independent director received 99.99% approval, with just 525 dissenting votes. The alteration of Article 76 of the Articles of Association also passed with 99.99% support, reflecting strong alignment between management and stakeholders on corporate governance changes.

Utilization of Proceeds

The proceeds from the warrant issue are structured to support long-term growth and operational liquidity. The company has committed to deploying the capital over an 18-month period from allotment. A significant portion, ₹53.00 crore, is allocated for working capital requirements, ensuring robust liquidity for day-to-day operations. Expansion of business operations accounts for ₹41.40 crore, targeting manufacturing upgrades in Punjab and Jammu & Kashmir. General corporate purposes are capped at ₹34.30 crore, adhering to the regulatory limit of 25% of the total consideration.

Strategic Expansion Details

The expansion component includes upgrading facilities at Jawaharpur and Derabassi in Punjab, as well as Samba in Jammu & Kashmir. A new warehouse will be established at the Derabassi site to enhance logistics efficiency. The company has also earmarked ₹2.00 crore for research and development of new formulations and pilot-scale equipment, signaling a push for product innovation. Technology upgrades, including SAP system implementation and Building Management Systems, will receive ₹1.50 crore. Furthermore, ₹5.00 crore is designated for investment in its subsidiary, ISLL Middle East LLC-FZ in Dubai, to drive marketing and business development in international markets.

Regulatory Compliance and Undertakings

The disclosure was made pursuant to Regulation 30 and Regulation 44(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Ind-Swift Laboratories has undertaken to recompute the price of specified securities if mandated by SEBI ICDR Regulations. Equity shares and warrants will remain locked-in until any payable amount arising from such re-computation is settled by the allottees. The company had previously issued a corrigendum on July 29, 2026, clarifying the utilization of proceeds in response to queries from the National Stock Exchange of India Limited (NSE) and BSE Limited. Pardeep Verma, VP - Corporate Affairs & Company Secretary, authorized the circulation of the meeting proceedings.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE915B01019/a79960dc-22ef-45cf-bf62-0e7a8415466a.pdf

Ind-Swift Laboratories has executed a memorandum of understanding with Him Infratech Private Limited for the construction of a centralized warehouse facility, marking a significant step in its infrastructure expansion plans. The agreement, signed on July 28, 2026, carries an estimated contract cost of ₹40 crore and is designed to enhance the company's storage capabilities and logistical efficiency. The new facility will be located on leasehold land spanning approximately 4.5 acres in Village Jawaharpur, Derabassi, Punjab, adjoining the company's existing manufacturing unit in the Global Business Unit.

The warehouse is projected to have a storage capacity of 11,000 pallets, dedicated to holding raw materials, packing materials, and finished goods. Ind-Swift Laboratories disclosed the transaction under Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing also referenced SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. The company confirmed that Him Infratech holds no shareholding in Ind-Swift Laboratories, and the transaction does not classify as a related-party transaction under the Listing Obligations and Disclosure Requirements.

Project Details

The construction timeline for the warehouse facility is set at 300 days, excluding any exigencies. The strategic location adjacent to the existing manufacturing facility in Derabassi allows for seamless integration with current operations. By centralizing storage for raw and finished goods, the company aims to reduce logistical bottlenecks and improve supply chain responsiveness. The absence of any shareholding or promoter-group relationship between the two entities ensures the transaction is conducted at arm's length.

Strategic Implications

This infrastructure investment underscores Ind-Swift Laboratories' focus on scaling its operational backbone to support future growth. The addition of a high-capacity centralized warehouse addresses potential constraints in storage and distribution, which are critical for maintaining product availability and reducing lead times. With the facility situated near its primary manufacturing hub in Punjab, the company can optimize inventory management and streamline the movement of goods from production to market. The execution of this MOU signals a commitment to long-term operational resilience and efficiency improvements within its supply chain framework.